Tumor Biology

, Volume 37, Issue 6, pp 7583–7587 | Cite as

RETRACTED ARTICLE: Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma

  • Hamid Reza Safaei
  • Ayoob Rostamzadeh
  • Omid Rahmani
  • Mohsen Mohammadi
  • Omar Ghaderi
  • Hamid Yahaghi
  • Koroosh Ahmadi
Original Article


In order to evaluate the correlation of B7-H4 and B7-H1 with renal cell carcinoma (RCC), we analyzed B7-H1 and B7-H4 expressions and their clinical significance by immunohistochemical method. Our result indicated that B7-H4-positive staining was detected in 58.13 % of RCC tissues (25 tissues tumors), and there were 18 tissues of patients without detectable B7-H4. Furthermore, 21 cases (48.83 %) were B7-H1-positive. Positive tumor expressions of B7-H4 and B7-H1 were markedly related to advanced TNM stage (P = 0.001; P = 0.014), high grade (P = 0.001; P = 002), and larger tumor size (P = 0.002; P = 024) in RCC tissues than patients with B7-H4-negative and B7-H1-negative in RCC tissues. The patients with B7-H1 and B7-H4-positive expressions were found to be markedly correlated with the overall survival of the patients (P < 0.05) and tended to have an increased risk of death when compared with negative expression groups. Univariate analysis showed that B7-H4 and B7-H1 expressions, TNM stage, high grade, and tumor size were significantly related to the prognosis of RCC. Furthermore, multivariate analysis showed that B7-H4 and B7-H1 expressions decreased overall survival. The adjusted HR for B7-H1 was 2.83 (95 % CI 1.210–2.971; P = 0.031) and also was 2.918 (95 % CI 1.243–3.102; P = 0.006) for B7-H4 that showed these markers were independent prognostic factors in RCC patients. The expressions of B7-H1 and B7-H4 in RCC patients indicate that these markers may be as a predictor of tumor development and death risk. Further investigations can be helpful to confirm B7-H1 and B7-H4 roles as an independent predictor of clinical RCC outcome.


B7-H1 and B7-H4 Renal cell carcinoma Analysis Prognosis Immunohistochemistry 


Compliance with ethical standards

Conflicts of interest



  1. 1.
    Howlader N, Noone AM, Krapcho M. SEER cancer statistics review, 1975–2011. Bethesda: National Cancer Institute; 2014.Google Scholar
  2. 2.
    Campbell SC, Novick AC, Bukowski RM. Renal tumors. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 9th ed. Philadelphia: Saunders; 2007. p. 1567–637.Google Scholar
  3. 3.
    McGuire BB, Fitzpatrick JM. Biomarkers in renal cell carcinoma. Curr Opin Urol. 2009;19:441–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Dutcher JP. Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol. 2013;5:338–53.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Dong H, Zhu G. Tamada K.B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Dong H, Strome SE, Salomao DR. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.CrossRefPubMedGoogle Scholar
  7. 7.
    Brown JA, Dorfman DM, Ma FR. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257–66.CrossRefPubMedGoogle Scholar
  8. 8.
    Konishi J, Yamazaki K, Azuma M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100.CrossRefPubMedGoogle Scholar
  9. 9.
    Wintterle S, Schreiner B, Mitsdoerffer M. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003;63:7462–7.PubMedGoogle Scholar
  10. 10.
    Ohigashi Y, Sho M, Yamada Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11:2947–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Curiel TJ, Wei S, Dong H. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Thompson RH, Gillett MD, Cheville JC. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl). 2003;81:281–7.CrossRefGoogle Scholar
  14. 14.
    Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Hirano F. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501–5.PubMedGoogle Scholar
  15. 15.
    Hirano F, Kaneko K, Tamura H, Dong H, Wang S. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089–96.PubMedGoogle Scholar
  16. 16.
    Iwai Y, Ishida M, Tanaka Y. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293–7.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18:849–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol. 2003;171:4650–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res. 2005;306:128–41.CrossRefPubMedGoogle Scholar
  20. 20.
    Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203(4):871–81.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006;103(27):10391–6.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Zisman A, Pantuck AJ, Dorey F. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649–57.PubMedGoogle Scholar
  23. 23.
    Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007;13:709s–15s.CrossRefPubMedGoogle Scholar
  25. 25.
    Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One. 2013;8(10):e76012.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53:143–51.CrossRefPubMedGoogle Scholar
  27. 27.
    Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 2005;11(5):1842–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Hamid Reza Safaei
    • 1
  • Ayoob Rostamzadeh
    • 2
  • Omid Rahmani
    • 3
  • Mohsen Mohammadi
    • 4
  • Omar Ghaderi
    • 5
  • Hamid Yahaghi
    • 6
  • Koroosh Ahmadi
    • 7
  1. 1.Department of Pediatric NephrologyAJA University of Medical SciencesTehranIran
  2. 2.Department of Anatomical Sciences, Faculty of MedicineShahrekord University of Medical SciencesShahrekordIran
  3. 3.Department of Pathology, Be’sat HospitalAJA University of Medical SciencesTehranIran
  4. 4.Department of Pharmaceutical Biotechnology, Faculty of PharmacyLorestan University of Medical SciencesKhorramabadIran
  5. 5.Department of Pharmaceutical BiotechnologyTehran University of Medical SciencesTehranIran
  6. 6.Department of Molecular BiologyBaqiyatallah University of Medical SciencesTehranIran
  7. 7.Department of Emergency MedicineAlborz University of Medical SciencesKarajIran

Personalised recommendations